- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management | 499 | Business Wire | Oral presentation during Presidential Plenary Session to feature the final results of the ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease (aGvHD) with gastrointestinal... ► Artikel lesen | |
| CLINIGEN GROUP Aktie jetzt für 0€ handeln | |||||
| 12.02. | Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort Enteral Solution, Human Milk-Based Product in Japan | 264 | PR Newswire | Clinigen obtained approval for Prolacta's "PreemieFort Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management... ► Artikel lesen | |
| 02.07.25 | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 748 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 34,235 | -2,64 % | DEUTSCHE BANK RESEARCH stuft NOVO NORDISK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 275 dänischen Kronen belassen. Analyst Emmanuel Papadakis verwies in einem... ► Artikel lesen | |
| GILEAD SCIENCES | 110,04 | -0,31 % | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the... ► Artikel lesen | |
| GSK | 21,800 | -6,96 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat GSK nach Quartalszahlen mit einem Kursziel von 1700 Pence auf "Underweight" belassen. Dass der Pharmakonzern die Erwartungen übertroffen habe,... ► Artikel lesen | |
| ASTRAZENECA | 156,75 | -1,69 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca vor den am 29. April erwarteten Quartalszahlen auf "Overweight" mit einem Kursziel von 16000 Pence belassen. Analyst... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 363,65 | -1,01 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VIATRIS | 12,844 | +1,44 % | Viatris' Q1 2026 Earnings: What to Expect | ||
| INCYTE | 86,00 | +2,99 % | Incyte Corporation Announces Climb In Q1 Bottom Line | WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) reported a profit for its first quarter that Increases, from last yearThe company's earnings totaled $303.33 million, or $1.47 per share. This... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 70,10 | -0,26 % | Edwards Lifesciences Corp. Q1 Income Rises | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) released a profit for its first quarter that Increases, from the same period last yearThe company's earnings came in at $380.7 million... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 62,80 | +2,38 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| GRIFOLS | 8,746 | -1,80 % | Grifols share results identifying early signs of Parkinson's disease | ||
| ALNYLAM PHARMACEUTICALS | 259,00 | +0,35 % | Bernstein SocGen cuts Alnylam stock price target on Amvuttra focus | ||
| LIGAND PHARMACEUTICALS | 204,00 | +2,51 % | Ligand Pharmaceuticals: Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator | Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary... ► Artikel lesen | |
| UNITED THERAPEUTICS | 481,00 | -1,07 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| PERRIGO | 9,882 | +0,49 % | Perrigo declares $0.29 dividend | ||
| DR REDDYS | 11,800 | +2,61 % | Dr. Reddy's Laboratories Secures Health Canada Approval For Diabetes Treatment Injection Launch In Canada |
Das Unternehmen CLINIGEN GROUP PLC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLINIGEN GROUP PLC finden Sie auf Wallstreet Online.